# SLC38A2

## Overview
SLC38A2 is a gene that encodes the protein solute carrier family 38 member 2, commonly referred to as SNAT2. This protein is a sodium-coupled neutral amino acid transporter, which plays a pivotal role in the cellular uptake of small neutral α-amino acids, such as glutamine, alanine, and serine, in a sodium ion-dependent manner. SNAT2 is characterized by its 11 transmembrane domains, facilitating its function as a transmembrane transporter protein (Galluccio2024Bacterial; Mackenzie2004Sodiumcoupled). It is widely expressed in various tissues, including muscle and brain, and is integral to cellular metabolism, protein synthesis, and the regulation of the mTORC1 signaling pathway, which is crucial for cell growth and proliferation (Mackenzie2004Sodiumcoupled; Hoffmann2018Effects). Additionally, SNAT2 exhibits a dual function as a 'transceptor,' not only transporting amino acids but also sensing amino acid sufficiency, thereby influencing its own expression and stability (Hoffmann2018Effects). The gene's expression and function are implicated in several physiological and pathological processes, including cancer metabolism and cellular response to osmotic stress (Bevilacqua2005SNAT2; Du2023Neutral).

## Structure
The SLC38A2 protein, also known as SNAT2, is a Na+-dependent transporter involved in the uptake of small and medium neutral amino acids. It consists of 11 transmembrane domains, with the N-terminal oriented towards the cytoplasm and the C-terminal facing outside the cell membrane (Galluccio2024Bacterial). This structural arrangement is typical for transport proteins, facilitating the movement of substrates across the cell membrane.

The primary structure of SLC38A2 includes lysyl residues within its N-terminal tail, which are crucial for its stability and regulation through ubiquitination. Mutations in these residues can lead to increased protein stability, indicating their role in substrate-induced destabilization (Hoffmann2018Effects).

While the exact tertiary structure of SLC38A2 is not fully characterized, studies have used homology models based on related proteins, such as SLC38A9, to predict potential binding sites for inhibitors. These models suggest a large vestibule required for binding, which may be a feature of its tertiary structure (GauthierColes2022Identification).

Post-translational modifications, such as phosphorylation, may influence the activity of SLC38A2, although specific details are not provided in the available context. The protein's function and regulation are also affected by sodium ion availability, which is essential for its amino acid transport activity (Hoffmann2018Effects).

## Function
SLC38A2, also known as SNAT2, is a sodium-coupled neutral amino acid transporter that plays a crucial role in the uptake of small neutral α-amino acids in a sodium ion-dependent manner. It is involved in the transport of amino acids such as glutamine, alanine, and serine, which are essential for cellular metabolism and protein synthesis (Mackenzie2004Sodiumcoupled). SNAT2 is widely expressed across various tissues, including muscle and brain, and is predominantly active in the plasma membrane (Mackenzie2004Sodiumcoupled).

The transporter is tightly regulated by nutritional and hormonal cues and is linked to the activation of the mTORC1 signaling pathway, a major regulator of cell growth, proliferation, and autophagy (Du2023Neutral; Hoffmann2018Effects). SNAT2 also exhibits a dual 'transceptor' function, where it not only facilitates amino acid transport but also senses amino acid sufficiency, influencing its own expression and stability (Hoffmann2018Effects).

In response to hyperosmotic stress, SNAT2 is upregulated to aid in the recovery of cell volume and maintain cellular homeostasis by increasing the intracellular amino acid pool, which is vital for counteracting osmotic stress (Bevilacqua2005SNAT2; Du2023Neutral).

## Clinical Significance
Alterations in the expression of the SLC38A2 gene have been implicated in various cancers, including gastric and breast cancer. In gastric cancer, SLC38A2 is significantly upregulated in tumor tissues compared to normal tissues, and its overexpression is associated with poor prognosis. The gene's upregulation is linked to increased tumor cell proliferation, invasion, and migration, suggesting its role in promoting tumorigenesis. Genetic alterations of SLC38A2, such as gene amplification, are observed in approximately 10% of gastric cancer patients. The gene is also involved in pathways like the Hippo signaling pathway, which is crucial for cell growth and apoptosis, indicating its potential as a therapeutic target (Zhu2023Comprehensive).

In breast cancer, particularly triple-negative breast cancer (TNBC), high SLC38A2 expression is associated with poor clinical outcomes. The gene contributes to glutamine dependence and oxidative stress resistance in cancer cells, which are critical for tumor survival and proliferation. SLC38A2 expression is linked to worse prognosis in TNBC patients, highlighting its potential as a prognostic marker and therapeutic target. The gene's role in regulating glutamine uptake and mitochondrial function is crucial for cancer cell survival, especially under hypoxic conditions (Morotti2019Hypoxiainduced; Morotti2020Increased).

## Interactions
SLC38A2, also known as SNAT2, is involved in several protein-protein interactions that are significant in the context of cancer metabolism. One notable interaction is with the SLC1A5 protein, another glutamine transporter. This interaction has been confirmed through proximity labeling proteomics and a bimolecular fluorescence complementation assay (BiFC), which demonstrated their co-localization on the plasma membrane and physical interaction (Huang2020SLC38A2). The interaction between SLC38A2 and SLC1A5 is thought to play a role in sustaining glutaminolysis, a metabolic pathway crucial for cancer cell survival and proliferation (Huang2020SLC38A2).

SLC38A2 also interacts with LAMP1, a lysosomal-associated membrane protein, in breast cancer cells. This interaction is involved in the degradation of SLC38A2 through autophagy, specifically via LAMP1-positive lysosomes, as confirmed by immunoprecipitation data (Morotti2020Increased). The interaction with LAMP1 suggests a role for SLC38A2 in modulating autophagy and lysosomal function, potentially acting as an amino acid sensor during nutrient starvation (Morotti2020Increased).

These interactions highlight the role of SLC38A2 in cellular metabolism and its potential impact on cancer prognosis and treatment strategies.


## References


[1. (Hoffmann2018Effects) Thorsten M. Hoffmann, Emma Cwiklinski, Dinesh S. Shah, Clare Stretton, Russell Hyde, Peter M. Taylor, and Harinder S. Hundal. Effects of sodium and amino acid substrate availability upon the expression and stability of the snat2 (slc38a2) amino acid transporter. Frontiers in Pharmacology, February 2018. URL: http://dx.doi.org/10.3389/fphar.2018.00063, doi:10.3389/fphar.2018.00063. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2018.00063)

[2. (Morotti2020Increased) Matteo Morotti, Christos E. Zois, Rokaya El-Ansari, Madeleine L. Craze, Emad A. Rakha, Shih-Jung Fan, Alessandro Valli, Syed Haider, Deborah C. I. Goberdhan, Andrew R. Green, and Adrian L. Harris. Increased expression of glutamine transporter snat2/slc38a2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. British Journal of Cancer, 124(2):494–505, October 2020. URL: http://dx.doi.org/10.1038/s41416-020-01113-y, doi:10.1038/s41416-020-01113-y. This article has 69 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41416-020-01113-y)

[3. (Mackenzie2004Sodiumcoupled) Bryan Mackenzie and Jeffrey D. Erickson. Sodium-coupled neutral amino acid (system n/a) transporters of the slc38 gene family. Pfl�gers Archiv European Journal of Physiology, 447(5):784–795, February 2004. URL: http://dx.doi.org/10.1007/s00424-003-1117-9, doi:10.1007/s00424-003-1117-9. This article has 410 citations.](https://doi.org/10.1007/s00424-003-1117-9)

[4. (GauthierColes2022Identification) Gregory Gauthier-Coles, Angelika Bröer, Malcolm Donald McLeod, Amee J. George, Ross D. Hannan, and Stefan Bröer. Identification and characterization of a novel snat2 (slc38a2) inhibitor reveals synergy with glucose transport inhibition in cancer cells. Frontiers in Pharmacology, September 2022. URL: http://dx.doi.org/10.3389/fphar.2022.963066, doi:10.3389/fphar.2022.963066. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2022.963066)

[5. (Galluccio2024Bacterial) Michele Galluccio, Martina Tripicchio, Lara Console, and Cesare Indiveri. Bacterial over-production of the functionally active human slc38a2 (snat2) exploiting the mistic tag: a cheap and fast tool for testing ligands. Molecular Biology Reports, February 2024. URL: http://dx.doi.org/10.1007/s11033-023-08976-3, doi:10.1007/s11033-023-08976-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11033-023-08976-3)

[6. (Bevilacqua2005SNAT2) Elena Bevilacqua, Ovidio Bussolati, Valeria Dall‧Asta, Francesca Gaccioli, Roberto Sala, Gian C. Gazzola, and Renata Franchi-Gazzola. Snat2 silencing prevents the osmotic induction of transport system a and hinders cell recovery from hypertonic stress. FEBS Letters, 579(16):3376–3380, May 2005. URL: http://dx.doi.org/10.1016/j.febslet.2005.05.002, doi:10.1016/j.febslet.2005.05.002. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.febslet.2005.05.002)

[7. (Zhu2023Comprehensive) Liang Zhu, Zhengguang Wang, Wenxiu Han, and Aman Xu. Comprehensive analysis of the biological function and immune infiltration of slc38a2 in gastric cancer. BMC Gastroenterology, March 2023. URL: http://dx.doi.org/10.1186/s12876-023-02689-4, doi:10.1186/s12876-023-02689-4. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12876-023-02689-4)

[8. (Du2023Neutral) Chunxiu Du, Hu Xu, Cong Cao, Jiahui Cao, Yufei Zhang, Cong Zhang, Rongfang Qiao, Wenhua Ming, Yaqing Li, Huiwen Ren, Xiaohui Cui, Zhilin Luan, Youfei Guan, and Xiaoyan Zhang. Neutral amino acid transporter slc38a2 protects renal medulla from hyperosmolarity-induced ferroptosis. eLife, February 2023. URL: http://dx.doi.org/10.7554/elife.80647, doi:10.7554/elife.80647. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.80647)

[9. (Morotti2019Hypoxiainduced) Matteo Morotti, Esther Bridges, Alessandro Valli, Hani Choudhry, Helen Sheldon, Simon Wigfield, Nicki Gray, Christos E. Zois, Fiona Grimm, Dylan Jones, Eugene J. Teoh, Wei-Chen Cheng, Simon Lord, Dimitrios Anastasiou, Syed Haider, Alan McIntyre, Deborah C. I. Goberdhan, Francesca Buffa, and Adrian L. Harris. Hypoxia-induced switch in snat2/slc38a2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences, 116(25):12452–12461, May 2019. URL: http://dx.doi.org/10.1073/pnas.1818521116, doi:10.1073/pnas.1818521116. This article has 92 citations.](https://doi.org/10.1073/pnas.1818521116)

[10. (Huang2020SLC38A2) Meng‐Sen Huang, Jen‐Hsuan Chang, Wen‐Ching Lin, Yu‐Hsiang Cheng, Fu‐An Li, Ching‐Shu Suen, Ming‐Jing Hwang, Chung‐ke Chang, and Kurt Yun Mou. Slc38a2 overexpression induces a cancer‐like metabolic profile and cooperates with slc1a5 in pan‐cancer prognosis. Chemistry – An Asian Journal, 15(22):3861–3872, October 2020. URL: http://dx.doi.org/10.1002/asia.202001056, doi:10.1002/asia.202001056. This article has 6 citations.](https://doi.org/10.1002/asia.202001056)